Large gap with delayed quotes
|
Last quote
10/17/2026
-
02:00:00
|
Bid
10/16/2026 -
21:59:59
|
Bid Volume |
Ask
10/16/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
66.39
-0.74
(
-1.10% )
|
66.34
|
200 |
66.41
|
1,900 |
Analysis date: 13.10.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 06.10.2026.
Quality
Weak
Weak
Two stars since 08.09.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 08.09.2026 at a price of 74.76.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 28.08.2026.
4wk Rel Perf
-14.56%
-14.56%
The four-week dividend-adjusted underperformance versus SP500 is 14.56%.
Risk
Middle
Middle
The stock has been on the moderate-sensitivity level since 06.10.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.45%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.78%.
Mkt Cap in $bn
12.85
12.85
With a market capitalization >$8bn, BRIDGEBIO PHARMA is considered a large-cap stock.
G/PE Ratio
2.53
2.53
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
17.74
17.74
The estimated PE is for the year 2028.
LT Growth
44.89%
44.89%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
17
17
Over the last seven weeks, an average of 17 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
63
63
For 1% of index variation, the stock varies on average by 0.63%.
Correlation
0.18
0.18
Stock movements are totally independent of index variations.
Value at Risk
7.60
7.60
The value at risk is estimated at USD 7.60. The risk is therefore 12.01%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
11.09.2020
11.09.2020